tiprankstipranks
Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
The Fly

Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development

Ionis Pharmaceuticals (IONS) announced that GSK (GSK) has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen, an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection. Ionis earned a $15M milestone payment from GSK associated with the progression of bepirovirsen into the Phase 3 clinical studies.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on IONS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles